General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | -1.27 | N/A | N/A | N/A |
2024-05-09 | 2024-03 | -1.28 | -1.5 | -0.22 | -17.19% |
2024-03-18 | 2023-12 | -2.8 | -2.3 | 0.5 | 17.86% |
2023-11-09 | 2023-09 | -3 | -3.3 | -0.3 | -10.00% |
2023-08-10 | 2023-06 | -3.2 | -3.1 | 0.1 | 3.13% |
2023-05-11 | 2023-03 | -3 | -2.9 | 0.1 | 3.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-04 | Truist Securities | Upgrade | Buy | Buy |
2023-08-10 | Chardan Capital | Upgrade | Neutral | Buy |
2023-03-06 | Ladenburg Thalmann | Upgrade | Buy | |
2022-11-10 | Chardan Capital | Upgrade | Neutral | |
2022-11-10 | RBC Capital | Upgrade | Sector Perform | |
2022-08-11 | Chardan Capital | Upgrade | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-09-18 | BECKMAN RICHARD L. | Officer | 39.06K | Sale |
2022-05-16 | D'SOUZA RUPERT | Chief Financial Officer | 20.85K | Purchase |
2023-03-14 | FISCHER LAURENT D M.D. | Chief Executive Officer | 692.14K | Sale |
2024-02-06 | LUPHER MARK L. JR., PH.D. | Director | 0.00 | Purchase |
2023-03-14 | RILEY BRIGIT | Officer | 117.44K | Sale |
2023-06-06 | RUBINSTEIN LINDA M. | Chief Financial Officer | 100.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Commodore Capital Lp | 10.00M | 15.90M | 9.90% |
2023-06-29 | FMR, LLC | 7.76M | 12.34M | 7.68% |
2023-06-29 | Morgan Stanley | 6.97M | 11.08M | 6.90% |
2023-06-29 | Bank of America Corporation | 5.59M | 8.89M | 5.54% |
2023-06-29 | Bml Capital Management, Llc | 5.16M | 8.20M | 5.11% |
2023-06-29 | Versant Venture Management, LLC | 5.07M | 8.06M | 5.02% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 6.90M | 12.01M | 6.83% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.66M | 4.23M | 2.64% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.23M | 1.95M | 1.21% |
2023-05-30 | Fidelity Extended Market Index Fund | 432.11K | 531.50K | 0.43% |
2023-06-29 | Fidelity Small Cap Enhanced Index Fund | 173.97K | 276.61K | 0.17% |
2023-05-30 | Fidelity Total Market Index Fund | 128.64K | 158.23K | 0.13% |
Split | Date |
---|---|
1 : 10 | 2024-03-21 |
I legit donโt think Iโve ever seen a company get FDA approval and DROP in price.
Another sell off by weak minded people
Just needs a little buying pressure
Picked up some more. Letโs march to $4
Picked up another 500 shares. See where we are in 30 days
There will be no holding it down when they announce the shot was not the cause of the problem...
Goldman Sachs just put a $10 price on this even with the possibility of the adverse reaction being from the injection. Median target of $7. Um, Iโll take 100% gains for $3.60 Alex...
Down on no volume. Thatโs called a buying opportunity
I think Sonic is run by a liberal Democrat. โLet no tragedy go to wasteโ. As yet there is no proven connection between the 1 patient going blind and the injection. Yet Sonic is running off at the mouth, without evidence, trying to ram in the changes they want...
If the investigation shows no connection between the injection and the patients unfortunate condition, will Sonic come out and commend the board for their successful phase II trials?
Well. It was a nice little run while it lasted... Waiting to add again
Sonic gonna be so mad....
Everyone taking pennies and running
Do some consolidation, take a little breather. Then we take the next leg up!
Man. If you didnโt pick up more on the $3.50โs....why?
Whatโs this? Share price has been driven below my current average price? Why sure, Iโll buy more!
Couldnโt do it today huh...?
Just waiting for the PR saying no correlation between the vaccine and the patient...
Letโs go shorts! I wanted more in the low to mid $3.50โs